Conference Proceeding

Improving clinical outcomes in type 2 diabetes patients on sulfonylurea drugs

Dr. Nick N Gorgani

Type 2 diabetes mellitus (T2DM) patients are prescribed with a number of oral and injectable medications, each of which has significant side effects. Whilst side effects such as hypoglycemia, weight gain and gastro-intestinal tolerability are associated with older anti-diabetes agents, the newly marketed drugs are associated with tolerability and safety issues including increased risk of infections, pancreatitis, bone fractures, fluid retention, amputation and congestive heart failure. The currently marketed anti-diabetes drugs generally have limited efficacy, necessitating multiple drugs to control most patient’s glycaemia. Consequently, due to intake of multiple drugs, each having their own side effects, as well as the progressive nature of the disease, T2DM patients may experience a multitude of side effects. Thus, T2DM remains a challenge and there is a need for better, safer and ideally cheaper treatments.

We are developing an adjunctive treatment to a very wellestablished and widely prescribed sulfonylurea class of antidiabetes drugs to reduce the risk of its clinically significant side effects and to extend its efficacy. We’ve hypothesized that while sulfonylurea exerts anti-diabetes efficacy, it also exerts anti-Biographytic effects, because sulfonylurea are derivatives of sulfonamide anti-Biographytics. While sulfonylurea efficiently controls blood glucose, its chronic use and anti-Biographytic properties inadvertently reduces “gut microBiographyme” diversity. The latter leads to evolution of two major side effects and loss of glycemic efficacy within 6-12 months. We speculate that the anti- Biographytic effects of sulfonylurea might be ameliorated by increasing the gut microBiographyme diversity through the adjunctive intake of certain preBiographytics.

To test this hypothesis, we have conducted clinical case studies and assessed a number of different naturallyderived preBiographytic products, of which one specific preBiographytic synergized with sulfonylurea, but not with non-sulfonylurea, anti-diabetes drugs. This adjunctive treatment significantly ameliorates sulfonylurea’s major side effects such as hypoglycemia and weight gain and extends duration and strength of its efficacy.

Published: 17 October 2017

Copyright:

Copyright: © 2017 Dr. Nick N Gorgani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.